CCA
CMPX icon

Cygnus Capital Advisors’s Compass Therapeutics CMPX Stock Holding History

Cygnus Capital Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95 Buy
18,000
+8,000
+80% +$46.2K 0.06% 62
2025
Q4 		$54 Buy
+10,000
New +$46.2K 0.04% 67

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cygnus Capital Advisors's CMPX Position: Q1 2026 in Review

Cygnus Capital Advisors increased its Compass Therapeutics (CMPX) stake by 80% in Q1 2026, buying an estimated $46.2K and bringing the position to 18,000 shares worth $95. The position accounts for 0.06% of the portfolio, ranked #62.

Cygnus Capital Advisors first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Cygnus Capital Advisors held 18,000 shares of Compass Therapeutics worth $95 as of Q1 2026.
  • Cygnus Capital Advisors bought 8,000 Compass Therapeutics shares in Q1 2026, an estimated $46.2K.
  • Compass Therapeutics made up 0.06% of Cygnus Capital Advisors's portfolio in Q1 2026, its #62 holding.
  • Cygnus Capital Advisors first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.